Vaccine targets to protect against multiple Salmonella types
Target Antigen Identification to Generate a Cross-serovar Salmonella Vaccine
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-11324315
This project aims to find parts of Salmonella bacteria that could be used to make a vaccine protecting people from different types that cause serious bloodstream infections.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA AT DAVIS (nih funded) |
| Locations | 1 site (DAVIS, UNITED STATES) |
| Trial ID | NIH-11324315 on ClinicalTrials.gov |
What this research studies
Researchers are building a new mouse model to compare how typhoid, paratyphoid, and non-typhoidal Salmonella cause disease and respond to vaccine strategies. They will look for bacterial pieces (antigens) that trigger liver-resident CD4 T cells to protect against multiple serovars. The team will test which antigens produce the strongest, lasting immune responses in the model. These lab and animal studies are an early step toward vaccines that could prevent severe systemic Salmonella infections in people.
Who could benefit from this research
Good fit: People at risk of systemic Salmonella infections—such as those exposed to typhoid, paratyphoid, or non-typhoidal serovars—would be the eventual candidates for vaccines developed from this research.
Not a fit: Because this is preclinical, it will not directly treat people with an active Salmonella infection now and may not immediately help those who are critically ill or severely immunocompromised.
Why it matters
Potential benefit: If successful, this work could lead to a vaccine that protects people against several major types of systemic Salmonella infections and reduce related illness and deaths.
How similar studies have performed: Typhoid conjugate vaccines exist, but developing a single vaccine that protects across typhoidal, paratyphoid, and non-typhoidal serovars is novel and largely untested in humans.
Where this research is happening
DAVIS, UNITED STATES
- UNIVERSITY OF CALIFORNIA AT DAVIS — DAVIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCSORLEY, STEPHEN J — UNIVERSITY OF CALIFORNIA AT DAVIS
- Study coordinator: MCSORLEY, STEPHEN J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.